No Data
No Data
Lion, Kobayashi Pharmaceutical, etc (additional) Rating
Target stock price change code stock name securities company previous changed after --------------------------------------------- <2607> Fuji Oil SMBC Nikko 3800 yen 4200 yen <2802> Ajinomoto SMBC Nikko 6800 yen 7200 yen <4043> Tokuyama Mizuho 3200 yen 3300 yen <4183> Mitsui Chemicals Nomura 4500 yen 4730 yen <4506> Sumitomo Pharma SMBC Nikko 600 yen 650 yen <4552> JCR Pharma
Anavex Gains After Seeking EU Marketing Nod for Alzheimer's Drug
Signed a collaborative research agreement with the National Center of Neurology and Psychiatry, initiating apolipoprotein E genetic testing in the AD DMT Registry.
On November 26, 2024, Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, hereinafter referred to as Eisai) and Biogen Japan Co., Ltd. (Headquarters: Tokyo, President: Yukisuke Tsutae, hereinafter referred to as Biogen Japan) have recently announced that Eisai has partnered with the National Center of Neurology and Psychiatry (NCNP) in Tokyo, an independent administrative institution engaged in mental and neurological healthcare research, to collaborate on various projects within NCNP as the leading research institution.
Idemitsu Kosan, Sumitomo Osaka Cement, etc. (additional) Rating
Upgraded - bullish code stock name brokerage firm previous changed after----------------------------------------------------------<9468>KADOKAWA Macquarie "Neutral" "Outperform" <5233> Taiheiyo Cement Daiwa "2" "1" target stock price change code stock name brokerage firm previous changed after----------------------------------------------
Rosevaramin Injectable 25mg for Amyotrophic Lateral Sclerosis (ALS) newly released in japan
Eisai Co., Ltd. (Headquarters: Tokyo, Representative Executive Officer/CEO: Haruo Naito) announced today the release of the drug "Rozeparamin Muscle Injection 25mg" (generic name: Mecobalamin) for amyotrophic lateral sclerosis (ALS) in Japan to "suppression of functional impairment progression in ALS". This drug obtained manufacturing and marketing approval on September 24, 2024, and today it is listed for premium listing. The approval of this drug was from national universities.
Anticancer drug "Tasfigo tablet 35mg" (generic name: Tasulugratinib hydrochloride)
On November 20, 2024, Eisai Co., Ltd. (Headquarters: Tokyo, Representative Executive Officer CEO: Haruo Naito) announced today the new launch in Japan of the selective tyrosine kinase inhibitor "Tasfigo Tablets 35mg" (generic name: Taslugratinib Dihydrochloride) for the indication of "unresectable cholangiocarcinoma positive for FGFR2 fusion gene that has worsened after cancer chemotherapy." This drug was approved on September 24, 2024.
No Data
No Data
